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The epidermal growth factor receptor (EGFR) plays
pivotal roles in development and is mutated or over-
expressed in several cancers. Despite recent ad-
vances, the complex allosteric regulation of EGFR re-
mains incompletely understood. Through efforts to
understand why the negative cooperativity observed
for intact EGFR is lost in studies of its isolated ex-
tracellular region (ECR), we uncovered unexpected
relationships between ligand binding and receptor
dimerization. The two processes appear to compete.
Surprisingly, dimerization does not enhance ligand
binding (although ligand binding promotes dimeriza-
tion). We further show that simply forcing EGFR
ECRs into preformed dimers without ligand yields
ill-defined, heterogeneous structures. Finally, we
demonstrate that extracellular EGFR-activating mu-
tations in glioblastoma enhance ligand-binding affin-
ity without directly promoting EGFR dimerization,
suggesting that these oncogenic mutations alter
the allosteric linkage between dimerization and lig-
and binding. Our findings have important implica-
tions for understanding how EGFR and its relatives
are activated by specific ligands and pathological
mutations.INTRODUCTION
X-ray crystal structures from 2002 and 2003 (Burgess et al.,
2003) yielded the scheme for ligand-induced epidermal growth
factor receptor (EGFR) dimerization shown in Figure 1. Binding
of a single ligand to domains I and III within the same extracellular
region (ECR) stabilizes an ‘‘extended’’ conformation and ex-
poses a dimerization interface in domain II, promoting self-asso-
ciation with a KD in the micromolar range (Burgess et al., 2003;
Dawson et al., 2005, 2007). Although this model satisfyingly ex-
plains ligand-induced EGFR dimerization, it fails to capture the1306 Cell Reports 9, 1306–1317, November 20, 2014 ª2014 The Autcomplex ligand-binding characteristics seen for cell-surface
EGFR, with concave-up Scatchard plots indicating either nega-
tive cooperativity (De Meyts, 2008; Macdonald and Pike, 2008)
or distinct affinity classes of EGF-binding site with high-affinity
sites responsible for EGFR signaling (Defize et al., 1989). This co-
operativity or heterogeneity is lost when the ECR from EGFR is
studied in isolation, as also described for the insulin receptor
(De Meyts, 2008).
Insight into structural origins of EGF/EGFR binding complexity
was provided by studies of the Drosophila melanogaster EGFR
(dEGFR), which, unlike its human counterpart, retains its nega-
tive cooperativity when the soluble ECR is isolated (Alvarado
et al., 2010). Crystal structures of the ECR from dEGFR revealed
a relatively simple ‘‘half-of-the-sites’’ reactivity in which occu-
pying one binding site in an asymmetric dimer restrains and re-
duces the ligand-binding affinity of the second site (Alvarado
et al., 2010). Subsequent detailed comparisons of human and
Drosophila receptor ECR dimer structures prompted experi-
ments that suggest a similar half-of-the-sites reactivity for hu-
man EGFR (hEGFR) (Liu et al., 2012). Moreover, detailed studies
of EGF binding to intact hEGFR in cells are consistent with this
model (Macdonald and Pike, 2008). The observed (or inferred)
negative cooperativity requires formation of a stable singly-li-
ganded receptor dimer, a species that is never seen for the iso-
lated human ECR (Lemmon et al., 1997) but forms readily for its
Drosophila counterpart (Alvarado et al., 2010). The ECR of the
Drosophila receptor even dimerizes significantly (KD 40 mM)
without bound ligand (Alvarado et al., 2009), reminiscent of the
ligand-independent (preformed) dimers reported for intact,
cell-surface hEGFR in many studies (Lemmon et al., 2014). We
therefore reasoned that artificially dimerizing the ECR from the
human receptor might restore negative cooperativity and pro-
vide avenues for studying details of the complex ligand-binding
characteristics of hEGFR. Indeed, engineered dimers of the
hEGFR ECR were previously reported to have increased
ligand-binding affinity and concave-up Scatchard plots (Adams
et al., 2009; Jones et al., 1999). Similarly, concave-up Scatchard
plots (suggesting negative cooperativity) were restored to the in-
sulin receptor ECR by fusing it to a dimeric immunoglobulin Fc
domain (Bass et al., 1996) or to a dimerizing leucine zipper
(Hoyne et al., 2000).hors
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Figure 1. Structural View of Ligand-Induced Dimerization of the hEGFR ECR
(A) Surface representation of tethered, unliganded, sEGFR from Protein Data Bank entry 1NQL (Ferguson et al., 2003). Ligand-binding domains I and III are green
and cysteine-rich domains II and IV are cyan. The intramolecular domain II/IV tether is circled in red.
(B) Hypothetical model for an extended EGF-bound sEGFR monomer based on SAXS studies of an EGF-bound dimerization-defective sEGFR variant (Dawson
et al., 2007) from PDB entry 3NJP (Lu et al., 2012). EGF is blue, and the red boundary represents the primary dimerization interface.
(C) 2:2 (EGF/sEGFR) dimer, from PDB entry 3NJP (Lu et al., 2012), colored as in (B). Dimerization arm contacts are circled in red.Here, we describe studies of an artificially dimerized ECR from
hEGFR that yield useful insight into the heterogeneous nature of
preformed ECR dimers and into the origins of negative coopera-
tivity. Our data also argue that extracellular structures induced
by ligand binding are not ‘‘optimized’’ for dimerization and con-
versely that dimerization does not optimize the ligand-binding
sites.We also analyzed the effects of oncogenicmutations found
in glioblastoma patients (Lee et al., 2006), revealing that they
affect allosteric linkage between ligand binding and dimerization
rather than simply promoting EGFR dimerization. These studies
have important implications for understanding extracellular
activating mutations found in EGFR/ErbB family receptors in
glioblastoma and other cancers and also for understanding
specificity of ligand-induced ErbB receptor heterodimerization.
RESULTS AND DISCUSSION
Predimerizing the EGFR ECR Has Modest Effects on
EGF Binding
To access preformed dimers of the hEGFR ECR (sEGFR) exper-
imentally, we C-terminally fused (to residue 621 of the mature
protein) either a dimerizing Fc domain (creating sEGFR-Fc) or
the dimeric leucine zipper from S. cerevisiae GCN4 (creating
sEGFR-Zip). Size exclusion chromatography (SEC) and/or sedi-
mentation equilibrium analytical ultracentrifugation (AUC) con-
firmed that the resulting purified sEGFR fusion proteins are
dimeric (Figure S1). To measure KD values for ligand binding to
sEGFR-Fc and sEGFR-Zip, we labeled EGF with Alexa-488
and monitored binding in fluorescence anisotropy (FA) assays.
As shown in Figure 2A, EGF binds approximately 10-fold more
tightly to the dimeric sEGFR-Fc or sEGFR-Zip proteins than to
monomeric sEGFR (Table 1). The curves obtained for EGF bind-
ing to sEGFR-Fc and sEGFR-Zip showed no signs of negative
cooperativity, with sEGFR-Zip actually requiring a Hill coefficientCell Re(nH) greater than 1 for a good fit (nH = 1 for both sEGFR
WT and
sEGFR-Fc). Thus, our initial studies argued that simply dimeriz-
ing human sEGFR fails to restore the negatively cooperative
ligand binding seen for the intact receptor in cells.
One surprise from these data was that forced sEGFR dimer-
ization has only amodest (%10-fold) effect on EGF-binding affin-
ity. Under the conditions of the FA experiments, isolated sEGFR
(without zipper or Fc fusion) remains monomeric; the FA assay
contains just 60 nM EGF, so the maximum concentration of
EGF-bound sEGFR is also limited to 60 nM, which is over 20-
fold lower than the KD for dimerization of the EGF/sEGFR com-
plex (Dawson et al., 2005; Lemmon et al., 1997). This%10-fold
difference in affinity for dimeric and monomeric sEGFR seems
small in light of the strict dependence of sEGFR dimerization
on ligand binding (Dawson et al., 2005; Lax et al., 1991; Lemmon
et al., 1997). Unliganded sEGFR does not dimerize detectably
even at millimolar concentrations, whereas liganded sEGFR di-
merizes with KD 1 mM, suggesting that ligand enhances dimer-
ization by at least 104- to 106-fold. Straightforward linkage of
dimerization and binding equilibria should stabilize EGF binding
to dimeric sEGFR similarly (by 5.5–8.0 kcal/mol). The modest
difference in EGF-binding affinity for dimeric and monomeric
sEGFR is also significantly smaller than the 40- to 100-fold differ-
ence typically reported between high-affinity and low-affinity
EGF binding on the cell surface when data are fit to two affinity
classes of binding site (Burgess et al., 2003; Magun et al., 1980).
Mutations that Prevent sEGFR Dimerization Do Not
Significantly Reduce Ligand-Binding Affinity
The fact that predimerizing sEGFR only modestly increased
ligand-binding affinity led us to question the extent to which
domain II-mediated sEGFR dimerization is linked to ligand bind-
ing. It is typically assumed that the domain II conformation stabi-
lized upon forming the sEGFR dimer in Figure 1C optimizes theports 9, 1306–1317, November 20, 2014 ª2014 The Authors 1307
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Figure 2. Dimerization of the ECR Has Little
Effect on Affinity for EGF
(A) FA data for Alexa-488-labeled EGF (EGF488)
binding to monomeric sEGFRWT (black triangles),
dimeric sEGFR-Fc (orange diamonds), and
dimeric sEGFR-Zip (blue circles). Ligand was
present at 60 nM for sEGFRWT experiments or
10 nM for sEGFR-Fc and sEGFR-Zip. Both
sEGFR-Fc and sEGFR-Zip are dimeric under these
conditions (Figure S1), whereas sEGFRWT remains
monomeric. Data shown are representative of
three independent experiments, with means listed
in Table 1.
(B) Representative ITC analysis of EGF binding to
sEGFRWT at 25C, with EGF at 80 mM in the syringe
and sEGFRWT at 10 mM in the cell.
(C) ITC analysis of EGF binding to the non-
dimerizing sEGFRY251A/R285S variant, performed as
in (B).
(D) SPR analysis of EGF binding to constitutively-
dimeric sEGFR-Fc, with (orange/black diamonds)
or without (solid orange diamonds) domain II
dimerization-disrupting mutations (Y251A/
R285S). All data are representative of three inde-
pendent experiments, with mean values (± SD)
noted. Mean values (± SD) of all thermodynamic
parameters are listed in Table 1.
See also Figures S1, S2, and S3.domain I and III positions for EGF binding. To test this hypothe-
sis, we introduced a well-characterized pair of domain II muta-
tions into sEGFRs that block dimerization: one at the tip of the
dimerization arm (Y251A) and one at its ‘‘docking site’’ on the
adjacent molecule in a dimer (R285S). The resulting (Y251A/
R285S) mutation abolishes sEGFR dimerization and EGFR
signaling (Dawson et al., 2005; Ogiso et al., 2002). Importantly,
we chose isothermal titration calorimetry (ITC) for these studies,1308 Cell Reports 9, 1306–1317, November 20, 2014 ª2014 The Authorswhere all interacting components are free
in solution. Previous surface plasmon
resonance (SPR) studies have indicated
that dimerization-defective sEGFR vari-
ants bind immobilized EGF with reduced
affinity (Dawson et al., 2005), and we
were concerned that this reflects avidity
artifacts, where dimeric sEGFR binds
more avidly than monomeric sEGFR to
sensor chip-immobilized EGF.
Surprisingly, our ITC studies showed
that the Y251A/R285S mutation has no
significant effect on ligand-binding affinity
for sEGFR in solution (Table 1). These ex-
periments employed sEGFR (with no Fc
fusion) at 10 mM—ten times higher than
KD for dimerization of ligand-saturated
WT sEGFR (sEGFRWT) (KD 1 mM).
Dimerization of sEGFRWT should there-
fore be complete under these conditions,
whereas the Y251A/R285S-mutated
variant (sEGFRY251A/R285S) does not
dimerize at all (Dawson et al., 2005). TheKD value for EGF binding to dimeric sEGFR
WT was essentially
the same (within 2-fold) as that for sEGFRY251A/R285S (Figures
2B and 2C; Table 1), arguing that the favorable Gibbs free energy
(DG) of liganded sEGFR dimerization (5.5 to 8 kcal/mol) does
not contribute significantly (<0.4 kcal/mol) to enhanced ligand
binding. Affinities of transforming growth factor a (TGF-a) for
sEGFRWT and sEGFRY251A/R285S were also indistinguishable, at
80 and 82 nM, respectively (Table S1). These ITC data lead to
Table 1. ITC Data for EGF Binding to sEGFR Variants
sEGFR Variant KD (nM)
a
DH
(kcal/mol)a
DG
(kcal/mol)b
TDS
(kcal/mol)c
sEGFR-Fc 7.8 ± 3.0d +10.3 ± 0.5e 11.1 21.4
sEGFR-Zip 8.9 ± 1.1d +12.3 ± 0.6e 11.0 23.3
sEGFRWT 78 ± 14d/
39 ± 4e
+6.9 ± 0.5e 9.7d/10.1e 16.6d/17.0e
sEGFRY251A/R285S 74 ± 10e +8.9 ± 1.0e 9.7 18.6
See also Table S1.
aValues are the mean ± SD of at least three independent experiments.
bDG values are calculated from the mean KD.
cTDS values are obtained by subtracting DG from the mean value for DH.
dFrom FA-based assay data.
eFrom ITC data.two important conclusions. First and most importantly, they
show that (without SPR avidity effects) domain II-mediated
dimerization does not significantly enhance ligand binding to
sEGFR, implying that there is no positive linkage between ligand
binding and sEGFR dimerization. Second, the results force us to
revise the interpretation of EGF/sEGFR ITC studies that we pub-
lished in 1997 (Lemmon et al., 1997). We previously ascribed the
major entropy-driven event (with positive DH) to sEGFR dimer-
ization, modeling EGF binding as an enthalpy-driven event
based on ITC of EGF binding to isolated domain III (Figure S2).
The fact that the entropy-driven event is maintained in the
absence of sEGFR dimerization refutes this and reveals that
EGF binding to the intact ECR is entropy driven, consistent
with the associated conformational changes (see Figure S2).
Thus, in contrast to the expected 104- to 106-fold enhance-
ment expected from straightforward linkage of sEGFR dimeriza-
tion and EGF binding, our data reveal that blocking sEGFR
dimerization has little influence on ligand-binding affinity.
Although DG for ligand binding is therefore essentially un-
changed by the Y251A/R285S mutation, the enthalpy change
(DH) associated with EGF binding is more favorable (less posi-
tive) by 2.0 kcal/mol for sEGFRWT than for sEGFRY251A/R285S.
Compensating for this, TDS is less favorable by 1.6 kcal/mol
for binding to sEGFRWT. Very similar results were obtained for
TGF-a (Figures S3A and S3B; Table S1). Moreover, direct com-
parison of ITC and FA experiments shows that EGF binds
sEGFRWT with very similar affinities regardless of whether it
does (in ITC experiments) or does not (in FA experiments)
dimerize (Table 1; Figures 2A and 2B), also arguing that ligand
binding and dimerization are not linked. Dimerization of EGF-
bound sEGFRWT is essentially complete in our ITC experiments
([EGF/sEGFR] reaches 10 mM) and is negligible in FA ([EGF/
sEGFR] % 60 nM), yet KD for EGF binding remains the same.
Moreover, even for covalently dimerized sEGFR-Fc, dimerization
arm mutations do not impair ligand binding, as shown in SPR
studies of EGFR binding by Fc-fused WT and Y251A/R285S-
mutated sEGFR (Figure 2D).
Thermodynamics of EGF Binding to sEGFR-Fc
If there is no discernible positive linkage between sEGFR dimer-
ization and EGF binding, why do sEGFR-Fc and sEGFR-Zip bind
EGF 10-fold more strongly than wild-type sEGFR? To investi-Cell Regate this, we used ITC to compare EGF binding to sEGFR-Fc
and sEGFR-Zip (Figures 3A and 3B) with binding to isolated (non-
fusion) sEGFRWT. As shown in Table 1, the positive (unfavorable)
DH for EGF binding is further elevated in predimerized sEGFR
compared with sEGFRWT, suggesting that enforced dimerization
may actually impair ligand/receptor interactions such as
hydrogen bonds and salt bridges. The increased DH is more
than compensated for, however, by a favorable increase in
TDS. This favorable entropic effect may reflect an ‘‘ordering’’
imposed on unliganded sEGFR when it is predimerized, such
that it exhibits fewer degrees of freedom compared with mono-
meric sEGFR. In particular, since EGF binding does induce
sEGFR dimerization, it is clear that predimerization will reduce
the entropic cost of bringing two sEGFR molecules into a dimer
upon ligand binding, possibly underlying this effect.
Possible Heterogeneity of Binding Sites in sEGFR-Fc
Close inspection of EGF/sEGFR-Fc titrations such as that in Fig-
ure 3A suggested some heterogeneity of sites, as evidenced by
the slope in the early part of the experiment. To investigate this
possibility further, we repeated titrations over a range of temper-
atures. We reasoned that if there are two different types of EGF-
binding sites in an sEGFR-Fc dimer, they might have different
values for heat capacity change (DCp), with differences that
might become more evident at higher (or lower) temperatures.
Indeed, DCp values correlate with the nonpolar surface area
buried upon binding (Livingstone et al., 1991), and we know
that this differs for the two Spitz-binding sites in the asymmetric
Drosophila EGFR dimer (Alvarado et al., 2010). As shown in Fig-
ure 3C, the heterogeneity was indeed clearer at higher tempera-
tures for sEGFR-Fc—especially at 25C and 30C—suggesting
the possible presence of distinct classes of binding sites in the
sEGFR-Fc dimer. We were not able to fit the two KD values (or
DH values) uniquely with any precision because the experiment
has insufficient information for unique fitting to a model with
four variables. Whereas binding to sEGFRWT could be fit confi-
dently with a single-site binding model throughout the tempera-
ture range, enforced sEGFR dimerization (by Fc fusion) creates
apparent heterogeneity in binding sites, which may reflect nega-
tive cooperativity of the sort seen with dEGFR. The different
binding sites are too close in their KD values to be discerned in
ITC or FA studies and can only be distinguished based on
different DH values at higher temperature. Nonetheless, these
data do suggest that negative cooperativity may be an intrinsic
property of the hEGFR ECR as suggested (Liu et al., 2012) and
as visualized for the Drosophila receptor (Alvarado et al., 2010).
Presumably, interactions involving other parts of EGFR are
responsible for the greater distinction in KD values seen for the
intact receptor in cells (Macdonald-Obermann and Pike, 2009).
Ligand Binding Is Required for Well-Defined
Dimerization of the EGFR ECR
To investigate the structural nature of the preformed sEGFR-Fc
dimer, we used negative stain electron microscopy (EM). We hy-
pothesized that enforced dimerization might cause the unli-
ganded ECR to form the same type of loose domain II-mediated
dimer seen in crystals of unliganded Drosophila sEGFR (Alvar-
ado et al., 2009). When bound to ligand (Figure 4A), the Fc-fusedports 9, 1306–1317, November 20, 2014 ª2014 The Authors 1309
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Figure 3. Evidence for Heterogeneity of Sites in Forced sEGFR Dimers
(A) Representative ITC data for EGF binding to sEGFR-Fc at 25C, with EGF at 130 mM in the syringe and sEGFR-Fc in the cell at 8.4 mM.
(B) ITC data for EGF binding to sEGFR-Zip at 25C, with EGF in the syringe at 105 mM and sEGFR-Zip in the cell at 11.3 mM. Mean DH values (± SD) from three
independent experiments are listed.
(C) ITC for EGF binding to sEGFR-Fc (upper) and sEGFRWT (lower) at the temperatures marked. EGF concentration in the calorimeter syringe was 80 mM, and
sEGFR protein was present in the cell at 9 mM. Data for sEGFR-Fc at 25C employed higher concentrations (25 mM sEGFR-Fc in the cell, 280 mM EGF in the
syringe) to improve signal to noise in discerning distinct binding events.ECR clearly formed the characteristic heart-shape dimer seen by
crystallography and EM (Lu et al., 2010;Mi et al., 2011). Figure 4B
presents a structural model of an Fc-fused liganded sEGFR
dimer, and Figure 4C shows a calculated 12 A˚ resolution projec-
tion of this model. The class averages for sEGFR-Fc plus EGF
(Figure 4A) closely resemble this model, yielding clear densities
for all four receptor domains, arranged as expected for the
EGF-induced domain II-mediated back-to-back extracellular
dimer shown in Figure 1 (Garrett et al., 2002; Lu et al., 2010). In
a subset of classes, the Fc domain also appeared well resolved,
indicating that these particular arrangements of the Fc domain
relative to the ECR represent highly populated states, with the
Fc domains occupying similar positions to those of the kinase
domain in detergent-solubilized intact receptors (Mi et al., 2011).
Without EGF, by contrast, EM analysis of sEGFR-Fc failed to
yield signal-enhanced class averages with interpretable interdo-
main relationships (Figure S4) despite significant effort with the
same protein preparations and staining conditions used for Fig-1310 Cell Reports 9, 1306–1317, November 20, 2014 ª2014 The Auture 4A. Thus, simply forcing the ECR from hEGFR into a dimer
by Fc fusion does not cause it to form well-ordered domain
II-mediated back-to-back dimers. Ligand binding is required
for this type of dimer to form. Whether the ECRs are tethered
or extended (or sample both conformations) in unliganded
sEGFR-Fc dimers is not clear. Solution small angle X-ray scat-
tering (SAXS) studies showed that sEGFR-Fc becomes sig-
nificantly more compact upon EGF binding, with the radius of
gyration (Rg) falling from 65.0 A˚ to 56.4 A˚ (Figure 4D) and the
maximum interatomic distance (Dmax) within the molecule falling
from 198 A˚ to 175 A˚ (Figure 4E). Values for Rg and Dmax for
ligand-bound sEGFR-Fc agree reasonably well (within 8%) with
those calculated for a back-to-back dimer model (Figure 4F,
model i). The relatively large Rg and Dmax values for sEGFR-Fc
in the absence of ligand (Figures 4D and 4E) are more consistent
with a model in which the ECRs are splayed apart, possibly while
remaining tethered. Indeed, a model in which two tethered EGFR
ECRs are attached to the Fc dimer and splayed maximallyhors
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Figure 4. Ligand-Binding Is Required for
Formation of the Domain II-Mediated
Back-to-Back Dimer
(A) Reference-free class averages from single-
particle EM images of negatively stained EGF/
sEGFR-Fc complexes.
(B) Model for an EGF/sEGFR-Fc complex derived
by appending an Fc domain to the EGF-bound
sEGFR dimer from PDB entry 3NJP (Lu et al.,
2012). EGF is blue (space filling), and ligand-
binding EGFR domains I and III are green.
Cysteine-rich domains II and IV are cyan, and the
Fc domain is orange.
(C) 2D projection from a calculated 12 A˚ resolution
map based on the model in (B), generated as
described in Supplemental Experimental Pro-
cedures.
(D–F) Rg values fromGuinier analysis of SAXS data
for 10–20 mM sEGFR-Fc with (black bar) or without
(open bar) a 1.3-fold molar excess of EGF (D). Rg
values calculated from the three models (i–iii)
shown in (F) are also plotted. (E) SAXS-derived
values of maximum interatomic distance (Dmax) for
sEGFR-Fc alone (open bar) and the EGF/sEGFR-
Fc complex (black bar). Calculated Dmax values for
the three models shown in (F) are also plotted. All
SAXS data represent the mean of four indepen-
dent experiments (± SD). (F) Three distinct struc-
tural models (i, ii, and iii) were constructed for
unliganded sEGFR-Fc. In model i, sEGFR forms
the back-to-back dimer seen in the presence of
ligand (or for unliganded Drosophila EGFR). In
models ii and iii, sEGFR retains the tethered
conformation, but the two sEGFR moieties in the
dimer are either maximally splayed apart (model ii)
or are adjacent (model iii). Rg and Dmax values
calculated for eachmodel are plotted in (D) and (E).
See also Figure S4.(Figure 4F, model ii) yields an Rg of 69 A˚ (compared with 65 A˚ for
unliganded sEGFR-Fc) and a Dmax value of 212 A˚ (compared with
198 A˚ for unliganded sEGFR-Fc). An Fc-fused dimer with the teth-
ered sEGFR moieties adjacent (Figure 4F, model iii) is more
compact, suggesting that unliganded sEGFR-Fc lies (on average)
between models ii and iii. Thus, our SAXS data also argue that
ligand binding is necessary for formation of the well-defined
domain II-mediated dimerization interface. Simply forcing the re-
ceptor molecules into close proximity is not sufficient, as Springer
and colleagues also concluded in related studies (Lu et al., 2012).Cell Reports 9, 1306–1317, NoOur results and those of Lu et al. (2012)
argue that preformed extracellular dimers
of hEGFR do not contain a well-defined
domain II-mediated interface. Rather,
the ECRs in these dimers likely sample a
broad range of positions (and possibly
conformations). This conclusion argues
against recent suggestions that stable
unliganded extracellular dimers ‘‘disfavor
activation in preformed dimers by as-
suming conformations inconsistent with’’
productive dimerization of the rest of thereceptor (Arkhipov et al., 2013). The ligand-free inactive dimeric
ECR species modeled by Arkhipov et al. (2013) in their computa-
tional studies of the intact receptor do not appear to be stable.
The isolated ECR from EGFR has a very low propensity for
self-association without ligand, with KD in the millimolar range
(or higher). Moreover, sEGFR does not form a defined structure
even when forced to dimerize by Fc fusion. It is therefore difficult
to envision how it might assume any particular autoinhibitory
dimeric conformation in preformed dimers. It has also been
argued that the unliganded ECR impedes dimerization drivenvember 20, 2014 ª2014 The Authors 1311
by the intracellular region (Endres et al., 2013). The orientational
flexibility of the ECR indicated by our EM and SAXS studies of
sEGFR-Fc and by studies from the Springer laboratory (Lu
et al., 2010, 2012; Mi et al., 2011) makes it difficult to imagine
how the ECR could sterically constrain dimerization mediated
by the other parts of EGFR. Moreover, if ligand binding activates
EGFR simply by removing steric constraints imposed by the
ECR, it is difficult to understand why specific mutations of
even single residues in the dimerization interface should block
activation (Dawson et al., 2005; Ogiso et al., 2002) and
conversely whymutations that destabilize the domain II/IV tether
are not activating (Mattoon et al., 2004; Walker et al., 2004).
Structural Implications of Weak Linkage between
Ligand Binding and Dimerization
It has typically been assumed that binding of a single ligand
molecule between domains I and III of an sEGFRmolecule stabi-
lizes a structure that resembles one half of the 2:2 receptor dimer
in Figure 1C. Indeed, this is the assumption in the model struc-
ture shown in Figure 1B. In addition, the domain II conformation
in a ligand-bound sEGFRmonomer is thought to be ideally suited
(or poised) for dimerization (Dawson et al., 2005, 2007). These
assumptions predict (and presume) that ligand binding and
dimerization are strongly positively linked for EGFR and sEGFR.
The lack of such linkage in our studies suggests that the domain
II conformation stabilized by EGF binding may in fact not be
optimal for dimerization. Indeed, the precise conformation of
domain II in a liganded sEGFR monomer is not known, even
though SAXS studies of a nondimerizing sEGFR variant showed
that it does become extended upon EGF binding, with the dimer-
ization arm exposed (Dawson et al., 2007). Our studies of the
Drosophila EGFR (Alvarado et al., 2010) also showed that re-
straining domain II conformation through interactions at the
dimerization interface can significantly impair ligand binding
affinity (this is the origin of negative cooperativity). With this pre-
cedent in mind, we suggest that domain II-mediated sEGFR
dimerization may distort the domain II conformation in a way
that actually compromises ligand binding to domains I and III.
Conversely, we suggest that the domain II conformation stabi-
lized by ligand binding may be suboptimal for dimerization. In
this scenario, ligand-binding and dimerization contacts would
exert opposing influences on domain II, effectively competing
with one another. This competition could effectively nullify the
expected positive linkage between ligand binding and dimeriza-
tion. If this view is correct, the ligand-bound sEGFR dimer visu-
alized by crystallography would reflect a ‘‘compromise’’ in which
domain II adopts a structure that is intermediate between the
ideal conformation for ligand binding and the ideal conformation
for domain II-mediated dimerization.
The precise role played by the ECR in EGFR activation has
been a subject of debate in recent years. The ECR was initially
viewed as a module that serves simply to drive ligand-induced
receptor dimerization (Burgess et al., 2003). Some more recent
data also support this view (Lu et al., 2010; Mi et al., 2011),
and this is the simple view that predicts positive linkage between
ligand binding and dimerization. Alternatively, the ECR has been
argued to function as a steric impediment to ligand-independent
receptor dimerization, relieved only when the ECR binds ligand1312 Cell Reports 9, 1306–1317, November 20, 2014 ª2014 The Aut(Chantry, 1995; Endres et al., 2013; Jura et al., 2009), as
mentioned above. In a third possibility, it is proposed that the
ligand-bound ECR dimer must achieve a particular conformation
in order for the receptor to be active (Alvarado et al., 2010; Arkhi-
pov et al., 2013; Lemmon et al., 2014; Liu et al., 2012; Wilson
et al., 2009). Although ligand binding certainly promotes ECR
dimerization—presumably by exposing the dimerization arm as
in Figure 1—the suggested domain II conformational compro-
mise between optimal ligand binding and optimal dimerization
should result in a particular structure, which may be required
for productive signaling. Different discrete structures (stabilized
by different ligands) may even signal differently (Wilson et al.,
2009). A similar compromise between dimerization and ligand
binding is also seen in our studies with TGF-a (Figure S3 and
Table S1), bolstering the view that this domain II conformational
competition may be functionally important.
Extracellular Oncogenic Mutations Observed in
Glioblastoma May Alter Linkage between Ligand
Binding and sEGFR Dimerization
Missense mutations in the hEGFR ECR were discovered in
several human glioblastoma multiforme samples or cell lines
and occur in 10%–15% of glioblastoma cases (Brennan et al.,
2013; Lee et al., 2006). Several elevate basal receptor phosphor-
ylation and cause EGFR to transform NIH 3T3 cells in the
absence of EGF (Lee et al., 2006). Thus, these are constitutively
activating oncogenic mutations, although the mutated receptors
can be activated further by ligand (Lee et al., 2006; Vivanco et al.,
2012). Two of the most commonly mutated sites in glioblastoma,
R84 and A265 (R108 and A289 in pro-EGFR), are in domains I
and II of the ECR, respectively, and contribute directly in inactive
sEGFR to intramolecular interactions between these domains
that are thought to be autoinhibitory (Figure 5). Domains I and
II become separated from one another in this region upon ligand
binding to EGFR (Alvarado et al., 2009), as illustrated in the lower
part of Figure 5. Interestingly, analogous mutations in the EGFR
relative ErbB3 were also found in colon and gastric cancers
(Jaiswal et al., 2013).
We hypothesized that domain I/II interface mutations might
activate EGFR by disrupting autoinhibitory interactions between
these two domains, possibly promoting a domain II conforma-
tion that drives dimerization even in the absence of ligand. In
contrast, however, sedimentation equilibrium AUC showed
that sEGFR variants harboring R84K, A265D, or A265V muta-
tions all remained completely monomeric in the absence of
ligand (Figure 6A) at a concentration of 10 mM, which is similar
to that experienced at the cell surface (Lemmon et al., 1997).
As withWT sEGFR, however, addition of ligand promoted dimer-
ization of each mutated sEGFR variant, with KD values that were
indistinguishable from those of WT. Thus, extracellular EGFR
mutations seen in glioblastoma do not simply promote ligand-in-
dependent ECR dimerization, consistent with our finding that
even dimerized sEGFR-Fc requires ligand binding in order to
form the characteristic heart-shaped dimer.
Interestingly, the ligand-binding affinity of sEGFR was signifi-
cantly increased by all of the glioblastoma-derived mutations
studied here (Figure 6B). The effects ranged from a 5-fold in-
crease for A265V to an almost 20-fold increase for R84K. Similarhors
A265
inactiveactive
R84
III
III
domain II domain I
liganded
unliganded
A265
R84
dimerization
arm
Figure 5. Location of EGFR Domain I/II Interface Mutations in Glio-
blastoma
Cartoon representations of sEGFR crystal structures in liganded (red) and
unliganded (cyan) states are shown, from PDB entries 1MOX (Garrett et al.,
2002) and 1YY9 (Li et al., 2005), aligned using domain I as reference. Side
chains of R84 and A265 are shown, where the majority of mutations have been
seen in glioblastoma (Lee et al., 2006; Vivanco et al., 2012) and where the
domains I/II separation is increased upon activation (lower panel).affinity increases were also seen for TGF-a binding (Figure S5).
ITC studies with EGF (Figure 6C) further revealed that the 5- to
20-fold increase in ligand-binding affinity (a 1–2 kcal/mol reduc-
tion in DG) for R84K and A265V variants can be accounted for by
DH values that are more favorable (less positive) by around
3 kcal/mol when compared with the values for WT sEGFR
(Table 1). The A265D variant differs (with a less favorable DH),
possibly because it introduces a charged group into a hydropho-
bic region of the protein. These data are consistent with a model
in which the glioblastoma mutations in the domain I/II interface
‘‘free up’’ domains I and II to occupy positions that permit
more optimal interactions with bound ligand. For example,
replacement of R84 with a lysine—seemingly a rather conserva-
tive substitution—may destabilize the domain I/II interface by
disrupting its hydrogen bond network.Cell ReWe suggest that domain I is normally restrained by domain I/II
interactions so that its orientation with respect to the ligand is
compromised. When the domain I/II interface is weakened with
mutations, this effect is mitigated. If this results simply in
increased ligand-binding affinity of the monomeric receptor,
the biological consequence might be to sensitize cells to lower
concentrations of EGF or TGF-a (or other agonists). However,
cellular studies of EGFR with glioblastoma-derived mutations
(Lee et al., 2006; Vivanco et al., 2012) clearly show ligand-inde-
pendent activation, arguing that this is not the key mechanism.
The domain I/II interface mutations may also reduce restraints
on domain II so as to permit dimerization of a small proportion
of intact receptor, driven by the documented interactions that
promote self-association of the transmembrane, juxtamem-
brane, and intracellular regions of EGFR (Endres et al., 2013;
Lemmon et al., 2014; Red Brewer et al., 2009).
One particularly interesting possibility is that the elevated
ligand-binding affinity caused by R84K, A265V, and A265D mu-
tations does not reflect enhanced ligand binding to monomeric
sEGFR, but instead reflects ‘‘rescue’’ of the expected linkage be-
tween ligand binding and dimerization so that that ligand binds
significantly more strongly to (mutated) dimers than to (mutated)
monomers. To achieve this, the domain I/II interface mutations
might reduce communication between the dimerization and
ligand-binding sites so that optimal domain II-mediated dimer-
ization has less of a restraining influence on the ligand-binding
site. The importance of influences on domain II conformation in
EGFR activation by glioblastoma mutations is also supported
by studies of tether mutations in EGFR that alter ligand binding
in almost exactly the same way, but do not activate the receptor
(and do not impact domain II). Mutations that disrupt the intra-
molecular tether seen in Figure 1A enhance ligand binding to
sEGFR to the same degree as the glioblastoma mutations (Elle-
man et al., 2001; Ferguson et al., 2003). Moreover, four different
types of tether-disrupting mutation all have essentially the same
effect on ligand-binding thermodynamics (Figure S6) as seen for
R84K or A265V (DH becomes more favorable by 4 kcal/mol).
None of these tether-disrupting mutations constitutively acti-
vates EGFR, however (Mattoon et al., 2004; Walker et al.,
2004). The key difference between the (nonactivating) tether mu-
tations and the (activating) glioblastoma mutations is that only
the latter directly influence domain II conformation, arguing
that domain II conformational effects are the key to oncogenicity
of R84K and A265V/D mutations.
CONCLUSIONS
Setting out to test the hypothesis that simply dimerizing the
EGFR ECR is sufficient to recover the negative cooperativity
lost when it is removed from the intact receptor, we were led
to revisit several central assumptions about this receptor. Our
findings suggest three main conclusions. First, we find that en-
forcing dimerization of the hEGFR ECR does not drive formation
of a well-defined domain II-mediated dimer that resembles
ligand-bound ECRs or the unliganded ECR from Drosophila
EGFR. Our EMand SAXS data show that ligand binding is neces-
sary for formation of well-defined heart-shaped domain II-medi-
ated dimers. This result argues that the unliganded extracellularports 9, 1306–1317, November 20, 2014 ª2014 The Authors 1313
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Figure 6. Effects of Glioblastoma Mutations on sEGFR Properties
(A) Sedimentation equilibrium AUC of sEGFR variants harboring glioblastomamutations. Data are plotted as the natural logarithm of absorbance at 280 nm (A280,
monitoring protein concentration) against (r2–r0
2)/2, for data obtained at 9,000 rpm at room temperature, where r is the radial position in the sample and r0 is the
radial position of the meniscus. For ideal species, this representation yields a straight line with slope proportional to molecular mass. Each sEGFR variant was
analyzed alone at 10 mM (open symbols) or at 5 mM with an added 1.2-fold molar excess of TGF-a (closed symbols)—TGF-a replacing EGF since it contributes
negligibly to A280. Without ligand, best fit molecular masses were 75 kDa (WT), 80 kDa (R84K and A265V), and 89 kDa (A265D). In the presence of TGF-a, single-
species fits yielded molecular masses of 157 kDa (WT), 141 kDa (R84K), 143 kDa (A265V), and 175 kDa (A265D). Estimated KD values (± SD) for sEGFR
dimerization in the presence of TGF-a, fit as described (Dawson et al., 2005), were 1.5 mM (R84K), 1.0 mM (A265V), and 4.8 mM (A265D) compared with 1.2 mM for
WT sEGFR.
(B) Ligand binding by each sEGFR variant was analyzed using SPR, flowing protein at a range of concentrations over immobilized EGF. Best fit KD values (±SD) for
EGF binding were 83 ± 4.4 nM (WT), 4.3 ± 1.5 nM (R84K), 16 ± 4.4 nM (A265V), and 8.6 ± 5.1 nM (A265D). Similar data for TGF-a are shown in Figure S5.
(C) ITC analysis of EGF binding to sEGFR variant harboring mutations found in glioblastoma patients, performed as in Figure 2B.
See also Figures S5 and S6.dimers modeled by Arkhipov et al. (2013) are not stable and that
it is improbable that stable conformations of preformed extra-
cellular dimers disfavor receptor activation by assuming confor-
mations that counter activating dimerization of the rest of the
receptor. Recent work from the Springer laboratory employing
kinase inhibitors to drive dimerization of hEGFR (Lu et al.,
2012) also showed that EGF binding is required to form heart-
shaped ECR dimers. These findings leave open the question of
the nature of the ECR in preformed EGFR dimers but certainly
argue that it is unlikely to resemble the crystallographic dimer
seen for unliganded Drosophila EGFR (Alvarado et al., 2009) or
that suggested by computational studies (Arkhipov et al., 2013).1314 Cell Reports 9, 1306–1317, November 20, 2014 ª2014 The AutSecond, our results suggest that enforcing dimerization of the
hEGFR ECR may restore some of the complexity in ligand bind-
ing seen for intact hEGFR (but lost for the isolated soluble ECR).
Although some heterogeneity in EGF-binding sites was restored
in ITC studies of sEGFR-Fc dimers, the difference in KD values
was too small to be quantitated with confidence, arguing that
simple dimerization fails to recapitulate fully the intact receptor’s
negative cooperativity. This finding supports arguments that the
transmembrane and/or intracellular regions of the receptor also
play an important role in defining negative cooperativity in
hEGFR (Adak et al., 2011; Macdonald-Obermann and Pike,
2009) and underlines the need to consider cooperation ofhors
interactions mediated by all domains within the intact or nearly
intact receptor (Arkhipov et al., 2013; Bessman and Lemmon,
2012). It is interesting that the relative contributions of intracel-
lular regions and ECRs to the allosteric properties of the receptor
appear to differ greatly between mammals and insects, where
negative cooperativity is recapitulated in the isolated ECR
(Alvarado et al., 2010). Similar differences can also be seen be-
tween human receptors within a family. For example, whereas
the characteristic concave-up Scatchard plots seen for the intact
insulin receptor can only be recapitulated for the isolated ECR of
that receptor by fusion to a dimerization domain (Bass et al.,
1996; Hoyne et al., 2000), the related IGF1 receptor ECR retains
negative cooperativity without such modifications (Surinya et al.,
2008). Differences in the relative contributions of intracellular and
ECRs to precise receptor regulation may have important
signaling relevance.
Third, our calorimetric studies of hEGFR show that ligand
binds to the ECR with the same affinity whether it is capable of
dimerizing or not, despite the fact that ligand binding is clearly
required for ECR dimerization. This result argues that ligand
binding is required to permit dimerization but that domain II-
mediated dimerization may compromise, rather than enhance,
ligand binding. Assuming flexibility in domain II, we suggest
that this domain serves to link dimerization and ligand binding
allosterically. Optimal ligand binding may stabilize one confor-
mation of domain II in the scheme shown in Figure 1 that is
then distorted upon dimerization of the ECR, in turn reducing
the strength of interactions with the ligand. Such a mechanism
would give the appearance of a lack of positive linkage between
ligand binding and ECR dimerization, and a good test of this
model would be to determine the high-resolution structure of a
liganded sEGFR monomer (which we expect to differ from a
half dimer). This model also suggests a mechanism for selective
heterodimerization over homodimerization of certain ErbB re-
ceptors. If a ligand-bound EGFR monomer has a domain II
conformation that heterodimerizes with ErbB2 in preference to
forming EGFR homodimers, this could explain several important
observations. It could explain reports that ErbB2 is a preferred
heterodimerization partner of EGFR (Graus-Porta et al., 1997)
and might also explain why EGF binds more tightly to EGFR in
cells where it can form heterodimers with ErbB2 than in cells
lacking ErbB2, where only EGFR homodimers can form (Li
et al., 2012). Moreover, if different EGFR agonists stabilize
slightly different domain II conformations, this view of a flexible
domain II as an allosteric link between ligand binding and dimer-
ization suggests hypotheses for how individual ligands might
induce subtly different receptor states or select for specific het-
erodimer signaling complexes (Wilson et al., 2009). Interestingly,
as our data with glioblastoma mutations suggest, alterations in
the allosteric communication between domain II and the adja-
cent ligand-binding domain I can also be oncogenic.
EXPERIMENTAL PROCEDURES
Reagents and Proteins
EGF and TGF-awere fromMillipore.WT andmutated sEGFR variants were ex-
pressed in Sf9 cells employing a baculovirus system as described previously
(Ferguson et al., 2000) (see Supplemental Experimental Procedures for
details).Cell ReBinding and Dimerization Analyses
Binding of ligand to sEGFR proteins and/or sEGFR dimerization was analyzed
using ITC, FA, SPR, or sedimentation equilibrium AUC, as summarized below.
Full details are provided in Supplemental Experimental Procedures.
ITC
ITC experiments employed a MicroCal ITC200 instrument. Proteins were dia-
lyzed overnight into 20 mM HEPES (pH 8.0) containing 150 mM NaCl and
3.4 mM EDTA. sEGFR concentration in the calorimeter cell ranged from 8 to
25 mM, and the concentration of ligand in the syringe ranged from 60 to
280 mM. Data were fit to a single-site binding model in ORIGIN. All titrations
were performed independently at least three times, and representative titra-
tions are shown. Values for DH and other parameters quoted as mean ± SD.
KD values were only fit for titrations in which c ([sites]/KD) was less than 250.
Titrations where c > 250 were used for DH determination only.
FA
EGFwas labeled using the Alexa Fluor 488 Protein Labeling Kit fromMolecular
Probes. Labeled EGF (EGF488) at 10 nM (for sEGFR-Fc and sEGFR-Zip) or
60 nM (for sEGFRWT) was incubated with varying amounts of sEGFR protein
for 30 min at room temperature in 20 mM HEPES (pH 8.0) containing
150 mM NaCl. Fluorescence polarization (FP) measurements were taken on
a Beacon instrument at 20C, converted to anisotropy, and analyzed as
described in Supplemental Experimental Procedures. Three independent titra-
tions were performed for each receptor variant.
SPR and AUC
SPR and AUC experiments were performed as previously reported (Dawson
et al., 2005), with details provided in Supplemental Experimental Procedures.
EM
Receptor samples at a concentration of 2 mg/ml in 25mMHEPES (pH 8.0) con-
taining 150 mM NaCl were applied to glow-discharged carbon grids and
stained with 0.75% uranyl formate. Images were collected on a Tecnai T12 mi-
croscope at 67,0003 magnification and operating at 120 keV and were
analyzed as described in Supplemental Experimental Procedures.
SAXS
Protein samples were prepared for SAXS at concentrations of 10–20 mM in
25 mM HEPES (pH 8.0) containing 150 mM NaCl, and 40 min exposures at
4C were performed on a Rigaku S-MAX3000 pinhole camera system, with a
Rigaku 007HF rotating anode source and a Rigaku 300 mm wire grid ASM
DTR 200 detector. Data were processed as described in Supplemental Exper-
imental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.10.010.
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